Close
Get it on Google Play

TranS1 (TSON) Receives FDA Clearance to Market AxiaLIF 2L

April 28, 2008 5:16 PM EDT
TranS1 Inc. (Nasdaq: TSON) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its AxiaLIF 2L, two level percutaneous lumbar fusion system, in the United States. The AxiaLIF 2L is designed to treat degenerative disc disease at both the L5-S1 and L4-L5 lumbar discs through a single, one and a half inch incision.

"The AxiaLIF 2L enables spine surgeons to perform, for the first time ever, a multi-level lumbar fusion with no disruption of functional, supportive soft tissue structures," stated Rick Randall, President and CEO of TranS1. "From a business perspective, the AxiaLIF 2L(tm) significantly expands the patient population eligible for TranS1's novel, least invasive treatments for low back pain and increases the potential product revenue TranS1 can realize from each surgical procedure."

TranS1 Inc. (TranS1) is medical device company focused on designing, developing and marketing products that implement its minimally invasive surgical approach to treat degenerative disc disease affecting the lower lumbar region of the spine. [SM]

You May Also Be Interested In





Related Categories

FDA